MedTrace Logo

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

NCT00412776 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2015-12-23

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of Proxinium plus best supportive care with best supportive care only for patients with squamous cell head and neck cancer.

Conditions

  • Carcinoma, Squamous Cell of Head and Neck
  • Carcinoma, Squamous Cell
  • Neoplasms, Squamous Cell
  • Head and Neck Neoplasms
  • Mouth Neoplasms
  • Head and Neck Cancer

Interventions

DRUG

Proxinium

700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression

Sponsors & Collaborators

  • Sesen Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Wendy Cuthbert · Viventia Biotech Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Argentina
  • Brazil
  • Croatia
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Italy
  • Mexico
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00412776 on ClinicalTrials.gov